Compare Gilead Sciences, Inc. (GILD) vs ProShares UltraShort Bloomberg Natural Gas ETF (KOLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs ProShares UltraShort Bloomberg Natural Gas ETF — how do they compare? Gilead Sciences, Inc. trades at $147 (market cap $182.09B), while ProShares UltraShort Bloomberg Natural Gas ETF trades at $26 (market cap $115.44M). The key difference: Gilead Sciences, Inc. is far larger — about 1577.4× ProShares UltraShort Bloomberg Natural Gas ETF's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while ProShares UltraShort Bloomberg Natural Gas ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and ProShares UltraShort Bloomberg Natural Gas ETF for 10 Days on average.
| GILD | KOLD | |
|---|---|---|
Market Cap | $182.09B | $115.44M |
Volume | 4,960,247 | 6,626,046 |
Sector | Health | Leveraged / Inverse |
52-Week High | $155.80 | $49.39 |
52-Week Low | $116.74 | $13.58 |
Typical Hold Time | 111 Days | 10 Days |
Enterprise Value | $205.15B | — |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $147.10, up 1.99% with bullish technical signals and strong analyst support. The stock shows mixed fundamentals with a P/E of 17.84 and robust gross margins of 79.59%, though recent net income margin turned negative at -10.64%. Recent quarterly earnings beat expectations, and the company announced significant HIV prevention partnerships expanding access to lenacapavir across Latin America.
Outlook remains positive with 65% analyst buy ratings and $151.14 consensus target, though investors face risks from negative profitability metrics and increased investing outflows. The stock's current position near pivot point resistance at $147 suggests potential for breakout if earnings momentum continues.
KOLD is trading at $24.84, down 5.8% over the past 24 hours amid bearish technical signals. The stock faces strong selling pressure with moving averages indicating a bearish trend and oscillators in neutral territory. Recent news highlights natural gas market volatility driven by record production levels and geopolitical tensions in the Middle East affecting energy commodities.
The outlook remains challenging with technical indicators pointing to continued downward pressure. Investment opportunities may emerge if the stock finds support near current levels, but risks include ongoing natural gas price volatility and geopolitical uncertainties. The bearish technical setup suggests cautious positioning is warranted until clearer fundamental catalysts emerge.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About ProShares UltraShort Bloomberg Natural Gas ETF
KOLD is an inverse leveraged ETF that seeks to provide two times (2x) the inverse daily performance of the Bloomberg Natural Gas Subindex. It is designed for investors looking to profit from falling natural gas prices.
Read more on KOLD →
